Welcome to our dedicated page for Bicycle Therapeutics SEC filings (Ticker: BCYC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bicycle Therapeutics plc filings document a clinical-stage pharmaceutical issuer whose Nasdaq-listed ADSs each represent one ordinary share. The company’s 8-K reports furnish quarterly and annual financial results, business highlights, program updates for nuzefatide pevedotin and the EphA2 pipeline, and leadership and board changes.
Proxy materials cover annual general meeting matters, director elections, executive compensation, equity awards, and shareholder voting procedures for the England and Wales company. The filings also identify the ordinary share and ADS registration structure, Nasdaq listing context, governance arrangements, and material-event disclosures tied to the company’s Bicycle technology and oncology pipeline.
Bicycle Therapeutics PLC Chief Financial Officer Travis Alvin Thompson received a grant of employee stock options for 60,000 Ordinary Shares on July 15, 2026. The options have an exercise price of $4.2100 per share, expire on July 15, 2036, and vest 25% on July 15, 2027 with the balance in 36 equal monthly installments.
BICYCLE THERAPEUTICS PLC reported that chief product and supply chain officer Michael Charles Ferguson Hannay received an employee stock option grant for 60,000 ordinary shares. The option has an exercise price of 4.21 per share, expires on July 15, 2036, and vests one-fourth on July 15, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter.
Bicycle Therapeutics plc reported that Chief Scientific Officer Michael Skynner received a grant of 60,000 employee stock options on July 15, 2026. These options allow purchase of Ordinary Shares at an exercise price of $4.2100 per share, expire on July 15, 2036, and vest with one-fourth on July 15, 2027 and the remainder in 36 equal monthly installments thereafter.
Bicycle Therapeutics plc reported that Chief Operating Officer Jennifer Scott Perry received an employee stock option grant covering 60,000 Ordinary Shares on July 15, 2026. The option has a $4.21 exercise price, expires July 15, 2036, and vests 25% on July 15, 2027, with the remainder vesting in 36 equal monthly installments.
Bicycle Therapeutics Chief Operating Officer Jennifer Scott Perry reported selling a total of 1,412 Ordinary Shares in open-market transactions on July 2 and July 6, 2026 at prices reported between $4.27 and $4.34 per share. According to the disclosure, these shares were sold to cover statutory tax withholding obligations arising from the vesting and settlement of RSUs under a mandated “sell to cover” arrangement, rather than as discretionary sales. The transactions were carried out under a Rule 10b5-1 trading plan adopted on March 27, 2025, and Perry continues to hold approximately 91,052 Ordinary Shares directly after the reported sales.
Bicycle Therapeutics plc Chief Scientific Officer Michael Skynner reported two small open-market sales of Ordinary Shares tied to tax withholding on vested equity awards. On July 2, 2026, he sold 1,859 shares at a weighted average price of $4.27 per share, followed by 532 shares on July 6, 2026 at a weighted average price of $4.31. A footnote explains these transactions were required "sell to cover" sales to satisfy statutory tax withholding obligations related to RSU vesting and were not discretionary. After these sales, Skynner directly held 157,171 Ordinary Shares.
BICYCLE THERAPEUTICS PLC chief executive Kevin Lee reported two small share sales that were executed solely to cover taxes on vested RSUs. On July 2, 2026, he sold 5,905 ordinary shares at a weighted average price of $4.27 per share, followed by 1,737 shares on July 6, 2026 at a weighted average price of $4.31. A footnote explains these “sell to cover” transactions were mandated by his award agreement to satisfy statutory tax withholding obligations and were not discretionary market sales. After these transactions, Lee directly owns 603,671 ordinary shares, so the 7,642 shares sold represent only a small fraction of his holdings.
BICYCLE THERAPEUTICS PLC executive Michael Charles Ferguson reported small share sales linked to tax withholding on vested RSUs. He sold a total of 1,761 Ordinary Shares in two open-market transactions at weighted average prices of about $4.27 and $4.31 per share. According to the footnotes, these sales were mandated under a "sell to cover" arrangement to satisfy minimum statutory tax obligations from RSU vesting, rather than discretionary trading. After these transactions, he directly holds 94,375 Ordinary Shares.
BICYCLE THERAPEUTICS PLC Chief Financial Officer Travis Alvin Thompson reported the sale of 923 Ordinary Shares in two open-market transactions. The shares were sold at weighted average prices around $4.27 and $4.31 to cover statutory tax withholding obligations on vested RSUs, as required by his award agreement. Following these mandated sell-to-cover transactions, he holds 64,441 Ordinary Shares directly.
BCYC submitted a Rule 144 notice concerning proposed sales of Common Stock and restricted stock units. The filing lists 12,513 restricted stock units dated 07/02/2026, 3,594 restricted stock units dated 07/03/2026, and notes 1,716 shares sold on 04/06/2026. The filing is a routine notice of intended resale under Rule 144.